Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Has results × elacestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 751 Carboplatin 652 Paclitaxel 606 Bevacizumab 590 pembrolizumab 576 Cisplatin 567 Gemcitabine 509 Docetaxel 475 Radiotherapy 459 Rituximab 446 Dexamethasone 412 Nivolumab 377 Doxorubicin 370 Fluorouracil 324 Capecitabine 320 Etoposide 302 Pemetrexed 278 Oxaliplatin 276 Cytarabine 276 Prednisone 266 Lenalidomide 264 fludarabine phosphate 258 Erlotinib Hydrochloride 252 Leucovorin 250 fludarabine 244 Trastuzumab 240 Vincristine 237 Bortezomib 237 Filgrastim 230 Cetuximab 224

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡